Legacy BioDesign Home

Recent News and Events

Dr. Joshua Stillahn joined Legacy as Scientist in 2016, after working in the integrated circuit industry. Dr. Stillahn was recently promoted to Senior Scientist

Dr. Ryan Holcomb was promoted to Principal Scientist, effective January 1, 2018, joining Dr. Robert Payne as our second Principal Scientist

According to ResearchGate, Dr. Manning has over 32,000 reads of his publications through 2022 and his work has been cited almost 10,000 times overall.
The review article, “Stability of Protein Pharmaceuticals: An Update”, published by Legacy scientists in 2010, has now been cited almost 700 times. It is recognized by Web of Science as a Highly Cited Article, of which only 1% are so designated.
In July/August 2018, this highly cited paper  (Manning et al., “Stability of Protein Pharmaceuticals: An Update, Pharm. Res, 2010, 27: 544-575) received enough citations to place it in the top 1% of the academic field of Pharmacology & Toxicology based on a highly cited threshold for the field and publication year.

The review article on buffers written by Legacy scientists (Zbacnik et al., J. Pharm. Sci. 2017106: 713-733) was listed as being of outstanding interest in a review article by Baek and Zydney, Current Opinion in Biotechnology 201853: 59-64)

Ryan Manning heads Great Lakes Bio Design (Charlotte, MI), with a focus on AF4 method development as well as, more recently, subvisible particle analysis of biopharmaceuticals. Great Lakes BioDesign (GLB) began operation in January of 2014. As part of our distributed analytical network, GLB has already contributed to multiple Legacy projects since its inception.